Sustained Release T3 Therapy: Animal Models and Translational Applications

Area of Science:

• Endocrinology
• Pharmacology
• Regenerative Medicine

Background:

• Standard hypothyroidism treatment involves levothyroxine (LT4), assuming endogenous deiodinases adequately convert it to triiodothyronine (T3).
• Growing evidence suggests deiodinases may not fully restore T3 levels, prompting investigation into liothyronine (LT3) as a therapeutic option.
• Current oral LT3 administration causes significant T3 fluctuations, differing from physiological levels.

Purpose of the Study:

• To review novel drug delivery strategies for liothyronine (LT3) in hypothyroidism treatment.
• To assess the potential of these new strategies in preclinical models and their translatability to human applications.

Main Methods:

• Review of emerging LT3 delivery systems, including slow-release formulations, liquid preparations, and hybrid molecules (e.g., T3 sulfate, poly-zinc-T3, glucagon-T3).
• Evaluation of advanced delivery methods like T3-loaded nanoparticles, subcutaneous implants, and stem cell-based thyroid regeneration.
• Analysis of existing data on the applicability of these strategies in animal models and their potential for human clinical use.

Main Results:

• Various novel delivery strategies for LT3 are under development to achieve more stable circulating T3 levels.
• These strategies aim to overcome the limitations of current oral LT3 administration and potentially improve therapeutic outcomes.
• Preclinical data and considerations for human translatability are discussed for each reviewed method.

Conclusions:

• New LT3 delivery strategies are crucial for optimizing hypothyroidism management beyond standard LT4 therapy.
• Further research and clinical trials are needed to validate the efficacy and safety of these innovative approaches in humans.
• These advancements hold promise for more effective and physiologically relevant thyroid hormone replacement.